Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication.

ABSTRACT: Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we designed and synthesized a set of ciclesonide-acetal (Cic-acetal) derivatives. Among designated compounds, some Cic-acetal derivatives with a linear alkyl chain exhibited strong viral copy-number reduction activities compared with Cic2. These compounds might serve as lead compounds for developing novel anti-COVID-19 agents.

SUBMITTER: Tsuji G 

PROVIDER: S-EPMC9014634 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature